Head-To-Head Analysis: Acusphere (OTCMKTS:ACUS) versus Surrozen (NASDAQ:SRZN)

Surrozen (NASDAQ:SRZN) and Acusphere (OTCMKTS:ACUS) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, risk and valuation.

Profitability

This table compares Surrozen and Acusphere’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Surrozen	-4,810.50%	N/A	-154.08%
Acusphere	N/A	N/A	N/A

Earnings and Valuation

This table compares Surrozen and Acusphere”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$3.48 million	85.14	-$242.03 million	($37.59)	-0.68
Acusphere	N/A	N/A	N/A	N/A	N/A

Acusphere has lower revenue, but higher earnings than Surrozen.

Institutional & Insider Ownership

66.6% of Surrozen shares are held by institutional investors. 31.7% of Surrozen shares are held by insiders. Comparatively, 4.6% of Acusphere shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for Surrozen and Acusphere, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	2	0	3	1	2.50
Acusphere	0	0	0	0	0.00

Surrozen currently has a consensus target price of $42.00, indicating a potential upside of 64.58%. Given Surrozen’s stronger consensus rating and higher possible upside, equities analysts clearly believe Surrozen is more favorable than Acusphere.

Summary

Surrozen beats Acusphere on 7 of the 9 factors compared between the two stocks.

About Surrozen

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

About Acusphere

Acusphere, Inc. operates as a specialty pharmaceutical company that develops and commercializes cardiovascular drugs. It offers Imagify (perflubutane polymer microspheres), a cardiovascular drug that evaluates myocardial perfusion and detects coronary artery disease. It provides Imagify as an injectable suspension. The company was formerly known as Polymers For Medicine, Inc. and changed its name to Acusphere, Inc. in March 2004. Acusphere, Inc. was founded in 1993 and is based in Watertown, Massachusetts.